Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.47 |
| ▸ | JAK2 | O60674 | 2/20 | 0.47 |
| ▸ | JAK1 | P23458 | 2/20 | 0.47 |
| ▸ | TYK2 | P29597 | 2/20 | 0.47 |
| ▸ | JAK3 | P52333 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1841198 | 0.93 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL1842194 | 0.92 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL1839555 | 0.91 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL1843641 | 0.90 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL1843950 | 0.89 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL13122651 | 0.89 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL6773162 | 0.89 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL7700888 | 0.89 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL7511959 | 0.88 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL13519703 | 0.88 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3246030-A1 | NOVEL ADENINE DERIVATIVES | GlaxoSmithKline LLC (US) | 2017-11-22 | — | — | EP | disclosed |
| EP-3246030-A1 | NOVEL ADENINE DERIVATIVES | GlaxoSmithKline LLC (US) | 2017-11-22 | — | — | EP | disclosed |
| EP-2320905-B1 | NOVEL ADENINE DERIVATIVES | GLAXOSMITHKLINE LLC (US) | 2017-06-28 | — | — | EP | disclosed |
| EP-2320905-B1 | NOVEL ADENINE DERIVATIVES | GLAXOSMITHKLINE LLC (US) | 2017-06-28 | — | — | EP | disclosed |
| US-8802684-B2 | Adenine derivatives | GLAXOSMITHKLINE LLC (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802684-B2 | Adenine derivatives | GLAXOSMITHKLINE LLC (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802684-B2 | Adenine derivatives | GLAXOSMITHKLINE LLC (US) | 2014-08-12 | — | — | US | disclosed |
| US-20140024664-A1 | NOVEL ADENINE DERIVATIVES | GLAXOSMITHKLINE LLC (US) | 2014-01-23 | — | — | US | disclosed |
| US-20140024664-A1 | NOVEL ADENINE DERIVATIVES | GLAXOSMITHKLINE LLC (US) | 2014-01-23 | — | — | US | disclosed |
| US-20140024664-A1 | NOVEL ADENINE DERIVATIVES | GLAXOSMITHKLINE LLC (US) | 2014-01-23 | — | — | US | disclosed |
| US-20120315291-A1 | PURINE DERIVATIVES AND THEIR PHARMACEUTICAL USES | GLAXOSMITHKLINE LLC (US) | 2012-12-13 | — | — | US | disclosed |
| US-20120315291-A1 | PURINE DERIVATIVES AND THEIR PHARMACEUTICAL USES | GLAXOSMITHKLINE LLC (US) | 2012-12-13 | — | — | US | disclosed |
| US-20120315291-A1 | PURINE DERIVATIVES AND THEIR PHARMACEUTICAL USES | GLAXOSMITHKLINE LLC (US) | 2012-12-13 | — | — | US | disclosed |
| WO-2011098451-A1 | PURINE DERIVATIVES AND THEIR PHARMACEUTICAL USES | GLAXOSMITHKLINE LLC (US) | 2011-08-18 | — | — | WO | disclosed |
| WO-2011098451-A1 | PURINE DERIVATIVES AND THEIR PHARMACEUTICAL USES | GLAXOSMITHKLINE LLC (US) | 2011-08-18 | — | — | WO | disclosed |
| US-20110144136-A1 | NOVEL ADENINE DERIVATIVES | GLAXOSMITHKLINE LLC (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144136-A1 | NOVEL ADENINE DERIVATIVES | GLAXOSMITHKLINE LLC (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144136-A1 | NOVEL ADENINE DERIVATIVES | GLAXOSMITHKLINE LLC (US) | 2011-06-16 | — | — | US | disclosed |
| EP-2320905-A1 | NOVEL ADENINE DERIVATIVES | Smithkline Beecham Corporation (US) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010018134-A1 | NOVEL ADENINE DERIVATIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144136-A1 | NOVEL ADENINE DERIVATIVES | STING1, IFNG, IFNAR1 | SMN1; SMN2 4705/4885NPC1 1904/4885RAB9A 534/4885 |
| US-20140024664-A1 | NOVEL ADENINE DERIVATIVES | IFNAR1, STING1, IFNG | SMN1; SMN2 4751/4885NPC1 1881/4885RAB9A 450/4885 |
| US-20120315291-A1 | PURINE DERIVATIVES AND THEIR PHARMACEUTICAL USES | STING1, IFNG, IRF3 | SMN1; SMN2 2726/4885NPC1 1151/4885RAB9A 1608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.